A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies
From MaRDI portal
Publication:2104157
Recommendations
- Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer
- Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant
- Some promising approaches to tumor-immune modelling
- Stability analysis of a mathematical model for glioma-immune interaction under optimal therapy
- Mathematical modeling, analysis, and simulation of tumor dynamics with drug interventions
Cites work
- A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
- A mathematical model of Imatinib and interferon-Alpha combined treatment of chronic myeloid leukemia
- A mathematical model of angiogenesis and tumor growth: analysis and application in anti-angiogenesis therapy
- A mathematical model of tumor-immune interactions
- Analysis of the computational singular perturbation reduction method for chemical kinetics
- Invariant manifold methods for metabolic model reduction
- Modeling immunotherapy of the tumor -- immune interaction
- On a modified version of ILDM approach: asymptotic analysis based on integral manifolds
- Predictive modeling of neuroblastoma growth dynamics in xenograft model after bevacizumab anti-VEGF therapy
- Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer
Cited in
(4)- A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy
- Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer
- A feedback control model of comprehensive therapy for treating immunogenic tumours
- A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
This page was built for publication: A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2104157)